[Image courtesy of Lilly]
Eli Lilly (NYSE:LLY) has announced that it would commercialize its Tempo personalized diabetes management platform in the U.S. before the end of 2022. The company anticipates full nationwide availability of the platform in 2023.Designed for adults with type 1 and 2 diabetes, the platform includes the Tempo Smart Button, a compatible app, and the Tempo Pen prefilled insulin pen. The Bluetooth-enabled smart button provides the app with custom insulin dose data. Lilly bills the technology as a ‘personalized diabetes management platform.’
The reusable Smart Button is a medical device that works with the company’s disposable insulin pens that won FDA approval in 2019 and 2020.
Indianapolis-based Lilly notes patients using the platform can make data-driven decisions to manage diabetes. In particular, the platform is designed to enable data sharing between a…